Corey M Gill1, Joshua Loewenstern2, John W Rutland2, Hanane Arib3, Margaret Pain2, Melissa Umphlett4, Yayoi Kinoshita4, Russell B McBride4,5, Joshua Bederson2, Michael Donovan4, Robert Sebra3,6, Mary Fowkes4, Raj K Shrivastava2. 1. Department of Neurosurgery, Icahn School of Medicine at Mount Sinai, One Gustave L. Levy Place, New York, NY, 10029, USA. corey.gill@icahn.mssm.edu. 2. Department of Neurosurgery, Icahn School of Medicine at Mount Sinai, One Gustave L. Levy Place, New York, NY, 10029, USA. 3. Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, USA. 4. Department of Pathology, Icahn School of Medicine at Mount Sinai, New York, NY, USA. 5. The Institute for Translational Epidemiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA. 6. Sema4, A Mount Sinai Venture, Stamford, CT, USA.
Abstract
BACKGROUND: Emerging evidence suggests that STK11 mutations may influence clinical outcome and response to immunotherapy in cancer. MATERIALS AND METHODS: Next-generation targeted sequencing of STK11 mutation status in a large cohort of 188 meningiomas. RESULTS: STK11 loss-of-function mutations were identified in 3.7% of meningiomas. STK11 mutations were found in both low- and high-grade lesions and samples from primary and recurrent disease. There was a 2.8-fold increased risk of death for patients whose meningioma harbored an STK11 mutation, after controlling for lesion grade and occurrence status. The median overall survival for patients with STK11-mutated meningiomas was 4.4 years compared with 16.8 years. CONCLUSION: These data identify recurrent STK11 mutations in a subset of meningiomas. Genotyping of STK11 is encouraged for meningioma patients undergoing immunotherapy-based therapy.
BACKGROUND: Emerging evidence suggests that STK11 mutations may influence clinical outcome and response to immunotherapy in cancer. MATERIALS AND METHODS: Next-generation targeted sequencing of STK11 mutation status in a large cohort of 188 meningiomas. RESULTS: STK11 loss-of-function mutations were identified in 3.7% of meningiomas. STK11 mutations were found in both low- and high-grade lesions and samples from primary and recurrent disease. There was a 2.8-fold increased risk of death for patients whose meningioma harbored an STK11 mutation, after controlling for lesion grade and occurrence status. The median overall survival for patients with STK11-mutated meningiomas was 4.4 years compared with 16.8 years. CONCLUSION: These data identify recurrent STK11 mutations in a subset of meningiomas. Genotyping of STK11 is encouraged for meningioma patients undergoing immunotherapy-based therapy.
Entities:
Keywords:
Central nervous system; Meningioma; Neurooncology; STK11; Sequencing
Authors: G H Su; R H Hruban; R K Bansal; G S Bova; D J Tang; M C Shekher; A M Westerman; M M Entius; M Goggins; C J Yeo; S E Kern Journal: Am J Pathol Date: 1999-06 Impact factor: 4.307
Authors: David N Louis; Arie Perry; Guido Reifenberger; Andreas von Deimling; Dominique Figarella-Branger; Webster K Cavenee; Hiroko Ohgaki; Otmar D Wiestler; Paul Kleihues; David W Ellison Journal: Acta Neuropathol Date: 2016-05-09 Impact factor: 17.088
Authors: Stefan Aretz; Dietlinde Stienen; Siegfried Uhlhaas; Steffan Loff; Walter Back; Constanze Pagenstecher; D Ross McLeod; Gail E Graham; Elisabeth Mangold; René Santer; Peter Propping; Waltraut Friedl Journal: Hum Mutat Date: 2005-12 Impact factor: 4.878
Authors: Esra A Akbay; Shohei Koyama; Julian Carretero; Abigail Altabef; Jeremy H Tchaicha; Camilla L Christensen; Oliver R Mikse; Andrew D Cherniack; Ellen M Beauchamp; Trevor J Pugh; Matthew D Wilkerson; Peter E Fecci; Mohit Butaney; Jacob B Reibel; Margaret Soucheray; Travis J Cohoon; Pasi A Janne; Matthew Meyerson; D Neil Hayes; Geoffrey I Shapiro; Takeshi Shimamura; Lynette M Sholl; Scott J Rodig; Gordon J Freeman; Peter S Hammerman; Glenn Dranoff; Kwok-Kin Wong Journal: Cancer Discov Date: 2013-09-27 Impact factor: 39.397
Authors: Ethan Cerami; Jianjiong Gao; Ugur Dogrusoz; Benjamin E Gross; Selcuk Onur Sumer; Bülent Arman Aksoy; Anders Jacobsen; Caitlin J Byrne; Michael L Heuer; Erik Larsson; Yevgeniy Antipin; Boris Reva; Arthur P Goldberg; Chris Sander; Nikolaus Schultz Journal: Cancer Discov Date: 2012-05 Impact factor: 39.397
Authors: Shohei Koyama; Esra A Akbay; Yvonne Y Li; Amir R Aref; Ferdinandos Skoulidis; Grit S Herter-Sprie; Kevin A Buczkowski; Yan Liu; Mark M Awad; Warren L Denning; Lixia Diao; Jing Wang; Edwin R Parra-Cuentas; Ignacio I Wistuba; Margaret Soucheray; Tran Thai; Hajime Asahina; Shunsuke Kitajima; Abigail Altabef; Jillian D Cavanaugh; Kevin Rhee; Peng Gao; Haikuo Zhang; Peter E Fecci; Takeshi Shimamura; Matthew D Hellmann; John V Heymach; F Stephen Hodi; Gordon J Freeman; David A Barbie; Glenn Dranoff; Peter S Hammerman; Kwok-Kin Wong Journal: Cancer Res Date: 2016-02-01 Impact factor: 12.701
Authors: Priscilla K Brastianos; Peleg M Horowitz; Sandro Santagata; Robert T Jones; Aaron McKenna; Gad Getz; Keith L Ligon; Emanuele Palescandolo; Paul Van Hummelen; Matthew D Ducar; Alina Raza; Ashwini Sunkavalli; Laura E Macconaill; Anat O Stemmer-Rachamimov; David N Louis; William C Hahn; Ian F Dunn; Rameen Beroukhim Journal: Nat Genet Date: 2013-01-20 Impact factor: 38.330
Authors: Corey M Gill; Joshua Loewenstern; John W Rutland; Hanane Arib; Margaret Pain; Melissa Umphlett; Yayoi Kinoshita; Russell B McBride; Joshua Bederson; Michael Donovan; Robert Sebra; Mary Fowkes; Raj K Shrivastava Journal: J Cancer Res Clin Oncol Date: 2021-03-14 Impact factor: 4.553